Exscientia (NASDAQ:EXAI) Rating Reiterated by Morgan Stanley

Exscientia (NASDAQ:EXAI)‘s stock had its “equal weight” rating reissued by investment analysts at Morgan Stanley in a report issued on Monday, Benzinga reports. They currently have a $7.00 target price on the stock. Morgan Stanley’s price target would indicate a potential upside of 59.82% from the stock’s previous close.

Separately, Bank of America cut shares of Exscientia from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $11.00 to $9.00 in a research report on Friday, January 5th.

Exscientia Stock Up 3.1 %

EXAI opened at $4.38 on Monday. The company has a 50 day moving average of $5.73 and a 200 day moving average of $5.85. The company has a market cap of $529.50 million, a PE ratio of -2.96 and a beta of 0.78. Exscientia has a 12 month low of $4.14 and a 12 month high of $9.12. The company has a current ratio of 6.22, a quick ratio of 6.22 and a debt-to-equity ratio of 0.05.

Exscientia (NASDAQ:EXAI) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.02. Exscientia had a negative net margin of 737.10% and a negative return on equity of 36.44%. The firm had revenue of $3.10 million during the quarter, compared to the consensus estimate of $41.63 million. On average, sell-side analysts expect that Exscientia will post -1.76 EPS for the current year.

Institutional Trading of Exscientia

Several hedge funds have recently added to or reduced their stakes in EXAI. GAMMA Investing LLC raised its stake in shares of Exscientia by 112.1% during the first quarter. GAMMA Investing LLC now owns 4,356 shares of the company’s stock valued at $25,000 after acquiring an additional 2,302 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Exscientia by 359.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,245 shares of the company’s stock valued at $34,000 after buying an additional 4,104 shares during the last quarter. Rathbones Group PLC purchased a new stake in shares of Exscientia during the third quarter valued at approximately $47,000. Tocqueville Asset Management L.P. purchased a new stake in shares of Exscientia during the third quarter valued at approximately $58,000. Finally, Walled Lake Planning & Wealth Management LLC purchased a new stake in shares of Exscientia during the fourth quarter valued at approximately $64,000. 41.58% of the stock is owned by institutional investors.

About Exscientia

Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy.